OU research leads to license agreementPublished: Friday, April 14, 2017 By: News OK Staff Reports Source: NewsOK.com
Immune therapy research developed by University of Oklahoma College of Medicine scientist William Hildebrand, Ph.D., has taken a significant step toward becoming a therapeutic that could one day help cancer patients.
Hildebrand, a George Lynn Cross Research Professor in the Department of Microbiology and Immunology, licensed his technology to the startup company Pure Protein in 1999. A subsidiary of that company, Pure MHC, this year entered into a research and license agreement with AbbVie, a global biopharmaceutical company. The agreement is to discover and validate peptide targets for use with T-cell receptor therapeutics in several types of cancer.
The agreement marks another success for Hildebrand's research and OU's commitment to helping researchers commercialize their discoveries. When Hildebrand arrived at the OU College of Medicine in 1993, he began following a three-phase approach for his research, each of which is still evolving.
Hildebrand has led a well-funded research laboratory at OU. Since he arrived, he has attracted more than $50 million in funding, is listed as an inventor on 77 patents and has written more than 120 publications.
Hildebrand also is the chief scientist for Pure Protein and its subsidiaries.